NeuroSense Therapeutics Ltd. — Form D
NeuroSense Therapeutics Ltd. of HERZLIYA, L3, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-25. The offering totals $4.5M, of which $4.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-04-25
- Form: D
- Accession: 0001213900-24-036191
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $4.5M
- Amount sold: $4.5M
- Investors: 1
- Date of first sale: 2024-04-15
- Revenue range: Decline to Disclose
- SEC file number: 021-511619
Issuer
- Name: NeuroSense Therapeutics Ltd.
- CIK: 0001875091
- Entity type: Corporation
- Jurisdiction: ISRAEL
- Address: 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, L3, 4672562
- Phone: +972-9-7996183
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Caren Deardorf | Director | Herzliya, L3 |
| Cary Claiborne | Director | Herzliya, L3 |
| Mark Leuchtenberger | Director | Herzliya, L3 |
| Niva Russek-Blum | Executive Officer | Herzliya, L3 |
| Christine Pelizzari | Director | Herzliya, L3 |
| Revital Mandil-Levin | Director | Herzliya, L3 |
| Or Eisenberg | Executive Officer | Herzliya, L3 |
| Hagit Binder | Executive Officer | Herzliya, L3 |
| Alon Ben-Noon | Director | Herzliya, L3 |
| Alon Ben-Noon | Executive Officer | Herzliya, L3 |
| Roy Golan | Director | Herzliya, L3 |
| Ferenc Tracik | Executive Officer | Herzliya, L3 |
Other filings by this issuer (2)
More